Novo Nordisk A/s Class B · OMXCOP:NOVO_B

Novo Nordisk A/s Class B — EASD 2010 Investor and analyst event

13 slides from Novo Nordisk A/s Class B's conference presentation, Sep 23, 2010

  1. Slide 1: EASD 2010 Investor and analyst event

    EASD 2010 Investor and analyst event 23 September 2010 Stockholm

  2. Slide 2: Forward-looking statements

    EASD 2010 presentation Slide no 2 Forward-looking statements Novo Nordisk’s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including the company’s Annual Report 2009 and Form 20-F, both filed with the SEC in February 2010 as well as this document and written info

  3. Slide 3: Strong emphasis on Victoza and the new-generation insulins

    EASD 2010 presentation Slide no 3 Strong emphasis on Victoza® and the new- generation insulins 31 project and product abstracts at EASD 2010* 18 15 12 9 6 3 0 Victoza® New-generation Levemir® NovoRapid® NovoNorm® insulins * Including research abstracts, Novo Nordisk has 56 abstracts at EASD 2010

  4. Slide 4: EASD 2010 presentation Slide no 4

    EASD 2010 presentation Slide no 4

  5. Slide 5: Degludec vs. glargine: Pharmacodynamic variability under steady state conditions

    EASD 2010 presentation Slide no 5 Degludec vs. glargine: Pharmacodynamic variability under steady state conditions Degludec and glargine: Individual Degludec and glargine: Individual clamp profiles within-subject variability in AUCGIR,0-24h Individual variation coefficient (%) Degludec Glargine 1200

  6. Slide 6: Degludec vs. glargine: Pharmacodynamic variability reduced 3-4 fold in steady state

    EASD 2010 presentation Slide no 6 Degludec vs. glargine: Pharmacodynamic variability reduced 3-4 fold in steady state Degludec and glargine: PK/PD model of day-to-day variability in GIR Degludec glargine Increasing risk of hypoglycaemia GIR (mg/kg/min) Optimal glycaemic control Increasing risk of hy

  7. Slide 7: EASD 2010 presentation Slide no 7

    EASD 2010 presentation Slide no 7

  8. Slide 8: Victoza vs. sitagliptin: Treatment outcome and improvement in treatment satisfaction

    EASD 2010 presentation Slide no 8 Victoza® vs. sitagliptin: Treatment outcome and improvement in treatment satisfaction Victoza® vs. sitagliptin: Glycaemic Victoza® vs. sitagliptin: Improvement control, weight change & side-effects in treatment satisfaction Higher negative Higher positive scores ind

  9. Slide 9: EASD 2010 presentation Slide no 9

    EASD 2010 presentation Slide no 9

  10. Slide 10: Victoza vs. exenatide: Frequency and magnitude of antibody formation

    EASD 2010 presentation Slide no 10 Victoza® vs. exenatide: Frequency and magnitude of antibody formation Victoza® vs. exenatide: antibody Exenatide: Correlation between levels in LEAD-6 antibody levels and change in HbA1c ≤20%B/T >20 and ≤50%B/T >50%B/T Victoza® antibodies Exenatide antibodies Mean

  11. Slide 11: EASD 2010 presentation Slide no 11

    EASD 2010 presentation Slide no 11

  12. Slide 12: Victoza: Weight loss is observed independently of gastro-intestinal side effects

    EASD 2010 presentation Slide no 12 Victoza®: Weight loss is observed independently of gastro-intestinal side effects Change in body weight at week 26 by Change in body weight at week 26 by gastro-intestinal adverse events (GIAE) nausea, vomiting and diarrhoea (NVD) No GIAE Some GIAE No NVD Some NVD

  13. Slide 13: Q&A session

    EASD 2010 presentation Slide no 13 Q&A session

Novo Nordisk — EASD 2010 Investor and analyst event on 6ix